Document › Details
Thomson Reuters. (11/29/10). "Press Release: Thomson Reuters Acquires GeneGo. Resulting Solutions Will Help Biopharma and Academic Researchers Design Better Drugs". Philadelphia, PA & London.
|Product||software tools (bioinformatics)|
|Index term||GeneGo–Thomson Reuters: investment, 201011 acquisition €na|
|Person||Brett-Harris, Jon (Thomson Reuters 201308 Managing Director of Thomson Reuters Life Sciences)|
Thomson Reuters today announced that it has acquired GeneGo, a leading provider of biology and disease information, analytics, and decision support solutions for pharmaceutical research and development.
Effective immediately, GeneGo will become part of the Healthcare & Science business of Thomson Reuters. Financial terms of the transaction were not disclosed.
The acquisition enables Thomson Reuters to provide the pharmaceutical, biotechnology, and academic research communities with solutions that provide better understanding of the underlying mechanism of disease and potential therapies. GeneGo's scientific expertise and assets in biology-driven drug discovery complement the Thomson Reuters life sciences portfolio that covers drug pipeline competitive intelligence, patents, and chemistry.
"Thomson Reuters now provides comprehensive decision support solutions to help researchers striving to bring more effective medications to market," said Jon Brett-Harris, executive vice president at Thomson Reuters. "There is an increasing need for biology content, detailed disease insights, and analytics to support R&D productivity and to enable a more personalized approach to medicine."
GeneGo's capabilities include:
* MetaBase™, a comprehensive and respected knowledge base in systems biology.
* Expertise in analytics, data management, and value-added services.
* An experienced management team and a skilled scientific staff.
* A successful track record deploying decision support systems.
GeneGo is headquartered in San Diego and has offices in Moscow and Michigan.
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.
Tel: +0044 207.433.4704
Record changed: 2016-03-19
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]